Clinical Trials Logo

Clinical Trial Summary

The goal of this clinical study is to learn about an investigational gene therapy product called AVB-101, which is designed to treat a disease called Frontotemporal Dementia with Progranulin Mutations (FTD-GRN). FTD-GRN is an early-onset form of dementia, a progressive brain disorder that affects behavior, language and movement. These symptoms result from below normal levels of a protein called progranulin (PGRN) in the brain, which leads to the death of nerve cells (neurons), affecting the brain's ability to function. The main questions that the study aims to answer are: 1. Is a one-time treatment with AVB-101 safe for patients with FTD-GRN? 2. Does a one-time treatment with AVB-101 restore PGRN levels to at least normal levels? 3. Could AVB-101 work as a treatment to slow down or stop progression of FTD-GRN? In this study there is no placebo (a dummy pill or treatment used for comparison purposes), so all participants will receive a one-time treatment of AVB-101 delivered directly to the brain, with follow-up assessments for 5 years.


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT06064890
Study type Interventional
Source AviadoBio Ltd
Contact AviadoBio Clinical Trials
Phone +44 203-089-7917
Email clinicaltrials@aviadobio.com
Status Recruiting
Phase Phase 1/Phase 2
Start date August 30, 2023
Completion date October 31, 2030

See also
  Status Clinical Trial Phase
Recruiting NCT05288842 - Tanycytes in Alzheimer's Disease and Frontotemporal Dementia
Recruiting NCT03272230 - Assessment of Apathy in a Real-life Situation, With a Video and Sensors-based System N/A
Active, not recruiting NCT03987295 - A Phase 2 Study to Evaluate Safety of Long-term AL001 Dosing in Frontotemporal Dementia (FTD) Patients (INFRONT-2) Phase 2
Withdrawn NCT05497817 - A Study to Evaluate Caregiver Connections Via Technology for Patients With Alzheimer's and Other Types of Dementia N/A
Recruiting NCT04918251 - EEG and TMS-based Biomarkers of ALS, MS and FTD
Completed NCT01002300 - Oxytocin and Social Cognition in Frontotemporal Dementia N/A
Completed NCT01890343 - Imaging Characteristics of Florbetapir 18F in Patients With Frontotemporal Dementia, Alzheimer's Disease and Normal Controls. Phase 2
Completed NCT00376051 - Serotonergic Function and Behavioural and Psychological Symptoms of Frontotemporal Dementia Phase 4
Terminated NCT00159198 - Amyotrophic Lateral Sclerosis and Frontotemporal Dementia Phase 1
Active, not recruiting NCT04516499 - Neurofilament Surveillance Project (NSP)
Recruiting NCT04747431 - A Study of PBFT02 in Patients With Frontotemporal Dementia and Progranulin Mutations (FTD-GRN) Phase 1/Phase 2
Completed NCT03636204 - A First in Human Study in Healthy Volunteers and in Participants With Frontotemporal Dementia With Granulin (GRN) Mutation Phase 1
Completed NCT01937013 - Impact of Emotional Mimicry and Oxytocin on Frontotemporal Dementia Phase 2
Active, not recruiting NCT05075187 - Epidemiological Study in FRONtoTemporal Dementia
Not yet recruiting NCT05004558 - Effects of Remote-based Resistance Training on Cardiometabolic Risk Factors, Cognitive Function, and Quality of Life in Adults Living With Alzheimer's Disease and/or Related Dementias N/A
Completed NCT02999282 - Rehabilitative Trial for the Rescue of Neurophysiological Parameters in Progranulin Deficient Subjects N/A
Completed NCT00594737 - Open Label Pilot Study of the Effects of Memantine on FDG-PET in Frontotemporal Dementia Phase 3
Recruiting NCT03225144 - Investigating Complex Neurodegenerative Disorders Related to Amyotrophic Lateral Sclerosis and Frontotemporal Dementia
Active, not recruiting NCT04993755 - A Phase 2a Study of TPN-101 in Patients With C9ORF72 ALS/FTD Phase 2
Recruiting NCT04114994 - Longitudinal Cognitive Assessment by BoCA